New pediatric cholesterol study data released by Esperion Therapeutics at European Atherosclerosis Society event

New pediatric cholesterol study data released by Esperion Therapeutics at European Atherosclerosis Society event
Esperion shares new trial data

Esperion Therapeutics unveiled data from its CLEAR Outcomes trial and the CLEAR PATH Phase 2 pediatric study at the European Atherosclerosis Society Congress 2026.

The presentations focused on advances in lipid-lowering therapies and their impact on pediatric and adult populations at risk for atherosclerotic cardiovascular disease. The new findings may inform future treatment guidelines and ongoing clinical development for cholesterol management in younger patients.

Earlier this year, Esperion Therapeutics estimated that U.S. heart failure care costs total $46 billion annually, according to company projections in a recent analysis. The company advocated for optimized therapy and increased patient education in the same statement. These initiatives coincide with Esperion’s continued focus on addressing cardiovascular risks across different age groups.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.